F. Farnebo et al., Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease, WORLD J SUR, 23(1), 1999, pp. 68-74
Assessment of the malignant potential of parathyroid tumors in the absence
of metastases can be difficult using morphologic criteria alone. In this st
udy we have examined a total of 58 parathyroid tumors (31 benign, 15 malign
ant, and 12 equivocal) from 54 patients using immunohistochemistry with mon
oclonal antibodies directed against the retinoblastoma (RB) protein and the
cell cycle-associated antigen Ki-67 to evaluate their role as diagnostic m
arkers. RE protein immunoreactivity was not useful for distinguishing betwe
en benign and malignant parathyroid tumors. Analysis of the proliferation m
arker Ki-67 showed that there was a trend toward more intense staining in t
he malignant cases. The Ki-67 labeling index was highest in the parathyroid
cancers (median 33) and lowest in the sporadic primary adenomas (median 2)
. An observation that might have clinical implications is that tumors from
patients with familial hyperparathyroidism linked to chromosome Iq showed a
high Ki-67 index, indicating strong proliferative activity (median 25). Th
is correlates well with the clinical observation of tumors with malignant p
otential in this syndrome. Because of the considerable overlap between grou
ps of tumors, Ki-67 is not suitable for definitive differentiation between
benign and malignant tumors. However, Ki-67 may give valuable information a
bout which patients should be followed more closely.